Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$19.23 – $21.27
31% from low
Sector
Asset Management
The Defiance Daily Target 2X Long TSLA ETF, often referred to as "the Fund," is structured to deliver magnified daily investment outcomes, aiming to reflect twice (200%) the daily percentage movement in the stock price of Tesla, Inc. (NASDAQ: TSLA). Given its focus on achieving leveraged daily results, this Fund is distinctly different from most conventional exchange-traded funds, and there is no certainty that it will consistently meet its stated daily target. It is important for investors to understand that this Fund is not designed, nor should it be anticipated, to provide double the cumulative performance of TSLA for periods extending beyond a single trading day.
No one on the platform currently holds TRIL.
No tracked institution reports a position in TRIL as of their last filing.
| Execution date | Ratio |
|---|---|
| 2014-11-20 | 1-for-30reverse |
No one on the platform has traded TRIL yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| TRILDefiance Trillion Dollar Club Index ETF | $19.86 | +0.37% | $1M | — |
| BENJHorizon Landmark ETF | $53.20 | -0.01% | $269M | — |
| BOEGLeverage Shares 2X Long BA Daily ETF | $12.02 | -2.00% | $721369 | — |
| FTIFFirst Trust Bloomberg Inflation Sensitive Equity ETF | $29.29 | +0.00% | $1M | — |
| FTKIFirst Trust Small Cap BuyWrite Income ETF | $19.65 | -0.77% | $950478 | — |
| HFEQUnlimited HFEQ Equity Long/Short ETF | $23.20 | -0.90% | $1M | — |
| IRVHGlobal X - Interest Rate Volatility & Inflation Hedge ETF | $18.74 | +0.00% | $1M | — |
Source: Financial Modeling Prep · peers by sector/industry
The Defiance Daily Target 2X Long TSLA ETF (the “Fund”) seeks daily leveraged investment results of two times (200%) the daily percentage change in the share price of Tesla, Inc. (NASDAQ: TSLA). Because the Fund seeks daily leveraged investment results, it is very different from most other exchange-traded funds and there is no guarantee that the Fund will meet its stated objective. The Fund should not be expected to provide 2 times the cumulative return of TSLA for periods greater than a single trading day.
Top constituents
top 11 · 175% of the fund
$KZIA with a " $TRIL -type" financing (raising almost as much $ as prior market cap) Bullish signal in terms of demand 🧐 Yesterday, shared 83% ORR in first six TNBC patients treated including one complete metabolic response (also responses in broad range of mets including lung, liver, bone, lymph & CNS) More validation for PAM (PI3K/Akt /mTOR) pathway, this time with oral, brain penetrant candidate $CELC $RLAY
View on StockTwits ↗$ABVX Abivax ref=$119 — Long adding today — most properly done deals are in confidentiality and thus charts often slide down into a surprise spike of deal announcement. As just one example of many, look up $TRIL Trillium bought out by PFE end of Aug 2021. I am NOT guaranteeing that this is the scenario here, BUT just relying on pretty frequent experience to say that as long as a priori thesis stands (bullish Obe) then the price decline and buyer exhaustion is “normal”. IF… https://www.investing.com/equities/stem-cell-therapeutics-corp.-advanced-chart
View on StockTwits ↗$TRIL $SMLMAHINDRA $BLUESTONE.NSE $JPPOWER.NSE
View on StockTwits ↗$ABUS You know, honestly we all got shafted here by $ROIV and our “CEO”. Anyone remember $TRIL thats the type of move I was expecting here I’m very disappointed.
View on StockTwits ↗@Treb3k well. As you see in these small bios they are usually killed in a day or two back down. But on the other hand when you see a trend you follow it. We have a trend and it’s upward. I think ededa is like $TRIL when all said n done.
View on StockTwits ↗$STRO $110M secondary (equal to market cap, echoes of $TRIL back in the day). Coupled with moving up initial data for their next-gen tissue factor-targeting exatecan ADC= multiple green flags (should be a good readout)
View on StockTwits ↗$TRIL The opportunity set remains meaningful, but only if discipline keeps pace with ambition. The market is increasingly intolerant of delays that stretch credibility. Without proof, upside scenarios remain hypothetical and heavily discounted. The market will respond to evidence, not speculation.
View on StockTwits ↗@pianoman439 i've had a couple very lucky ones like $TRIL and $ARQL, but most just end up in the never ending death spiral of reverse split, dilute, repeat unless mercy takeover by a private co then name change
View on StockTwits ↗There’s a select group of public companies who have exceeded a market capitalization of a trillion dollars or more. And now, they have their very own ETF. $TRIL https://share.thenew.money/article/theres-a-new-etf-on-wall-street-for-trillion-dollar-companies-and-assets
View on StockTwits ↗@Polip you wouldn't believe me if i told you, LOL! Just curious, are you the same Polip that posted about $TRIL and/or $CYNA back in the day?
View on StockTwits ↗@WAJeff under 5k watchers falls into "under radar" name category. Of course there will.be exceptions - $TRIL for example, but that's very rare.
View on StockTwits ↗$PPBT The Biotech Playbook in Motion Volume spikes. Price suppression. Troll surge. Seen it before: $IMMU, $ARNA, $TRIL. Same setup. Same silence. Same endgame. Retail’s not rattled. Shorts are.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.